. . . .Dr. Dennis Hidlebaugh
Dr. Hidlebaugh is anticipated to testify about his medical background, training, and experience. Dr. Hidlebaugh is anticipated to testify that, beginning in 2003, he and his partners continued filling the Fosamax prescription for Linda Secrest based upon the initial prescription decision of Dr. Epstein. Dr. Hidlebaugh is anticipated to testify that, in light of the infonnation disclosed in the MDL deposition of Dr. Arthur Santora of Merck, and the review by Dr. Anthony Mucci, Plaintiffs Exhibit 1.0097, he no longer would prescribe it to a patient after three or four years of use. He is further anticipated to testify that Linda Secrest took Fosamax through early 2005.
Dr. Hidlebaugh will also testify regarding his familiarity with the Fosamax labels, and that there was no warning concerning osteonecrosis of the jaw or the risk of injury to the jaw bones before the Summer of 2005 and that had he know of any such warning, he would have discontinued the use of Fosamax for her. Further, Dr. Hidlebaugh will also testify that from 1998 to 2005, no Merck sales representative advised him ofthe risks of osteonecrosis of the jaw or jaw bone damage from Fosamax.
In addition to the foregoing, the bases for Dr. Hidlebaugh’s opinions include the MDL deposition of Dr. Arthur Santora, the FDA Biostatistical Review by Dr. Anthony Mucci (Exh. 1.0097), and Dr. Hidleabaugh’s medical records and chart for Linda Secrest. . . .
We’ll keep you informed, here.